Dilution Risk Roundup

DilutionWatch Weekly Roundup — July 14, 2026

Published July 14, 2026
By Redley LaMar  ·  DilutionWatch Analyst
Top dilution risks this week: JPM-PC, ECDA, ERNA, TCRT, SLXN, BCAB. DilutionWatch weekly roundup.

ECDA has 43.7% warrant coverage and 8 dilution filings in 12 months. SLXN has 73,953.9% warrant coverage and 10 dilution filings. The week’s theme is a cluster of biotech and financial firms with severe dilution risks, including a 73,953.9% warrant coverage and 10 filings. The pattern repeats.

These companies share a common thread: they are all in sectors with high capital intensity and frequent fundraising. Biotech firms like ERNA, SLXN, and Alaunos require substantial cash to advance clinical trials, while JPMorgan’s financial model relies on capital adequacy. The data reveals a sector-wide trend of rapid dilution, with some companies facing extreme warrant coverage and minimal cash runway.

That math is brutal.

Week’s Theme

The week’s theme is a cluster of biotech and financial firms with severe dilution risks. ECDA has 43.7% warrant coverage and 8 dilution filings in 12 months. SLXN has 73,953.9% warrant coverage and 10 dilution filings. The pattern repeats.

These companies share a common thread: they are all in sectors with high capital intensity and frequent fundraising. Biotech firms like ERNA, SLXN, and Alaunos require substantial cash to advance clinical trials, while JPMorgan’s financial model relies on capital adequacy. The data reveals a sector-wide trend of rapid dilution, with some companies facing extreme warrant coverage and minimal cash runway.

Watch the cash, not the price.

JPMorgan Chase & Co. (JPM-PC)

Score: 48/100 (MEDIUM). Cash runway: 4.6 months. Warrant coverage: 3.3%. Shares up 7.8% over 3 years. 3 dilution filings in 12 months. The company has a low but persistent dilution risk, primarily due to its warrant coverage and multiple filings. The risk lies in its exposure to market volatility and regulatory pressures.

That math is brutal.

JPMorgan’s 3.3% warrant coverage and 4.6-month cash runway suggest a moderate dilution risk, but the 3 filings in 12 months signal ongoing capital needs. The firm’s performance over the past three years shows modest growth, but the market could react negatively to further dilution.

ECD Automotive Design Inc (ECDA)

Score: 100/100 (CRITICAL). Cash runway: 0.2 months. ATM remaining: $500.0M. Warrant coverage: 43.7%. Shares up 241.3% over 3 years. 8 dilution filings in 12 months. ECDA has the highest dilution risk with a cash runway of just 0.2 months and a $500M ATM facility. The 43.7% warrant coverage and 8 filings over 12 months make it a high-risk stock.

Watch the cash, not the price.

ECDA’s 0.2-month cash runway is a critical risk factor. The company relies heavily on its ATM facility, and the 8 filings in 12 months suggest ongoing capital needs. The 43.7% warrant coverage means a significant portion of shares could be diluted if warrants are exercised, leading to further price pressure.

Ernexa Therapeutics Inc. (ERNA)

Score: 99/100 (CRITICAL). Cash runway: 3.7 months. ATM remaining: $10.0M. Warrant coverage: 523.0%. Shares up 3,349.2% over 3 years. 6 dilution filings in 12 months. ERNA has an extremely high warrant coverage of 523%, indicating a significant risk of share dilution. The 3.7-month cash runway and 6 filings over 12 months signal ongoing capital needs and high risk.

That math is brutal.

ERNA’s 523% warrant coverage is an extreme red flag. The company has raised $10M through its ATM facility, but its 3.7-month cash runway suggests a need for more capital. The 6 filings in 12 months show a pattern of frequent fundraising, which could lead to further dilution and stock price declines.

Alaunos Therapeutics, Inc. (TCRT)

Score: 98/100 (CRITICAL). Cash runway: 0.3 months. Warrant coverage: 77.5%. Shares up 1,117.9% over 3 years. 5 dilution filings in 12 months. TCRT has a 0.3-month cash runway and 77.5% warrant coverage, making it a high-risk stock. The 5 filings in 12 months indicate frequent capital raising, which could lead to further dilution.

Watch the cash, not the price.

TCRT’s 0.3-month cash runway is extremely low, and the 77.5% warrant coverage suggests a high risk of share dilution. The 5 filings in 12 months show a pattern of frequent fundraising, which could lead to further price pressure and investor concerns about the company’s financial stability.

Silexion Therapeutics Corp (SLXN)

Score: 98/100 (CRITICAL). Cash runway: 2.5 months. Warrant coverage: 73,953.9%. Shares up 671.0% over 3 years. 10 dilution filings in 12 months. SLXN has the highest warrant coverage of 73,953.9%, which is extremely risky. The 2.5-month cash runway and 10 filings in 12 months suggest a high probability of further dilution.

That math is brutal.

SLXN’s 73,953.9% warrant coverage is a major concern. The company has raised $10M through its ATM facility, but its 2.5-month cash runway suggests a need for more capital. The 10 filings in 12 months show a pattern of frequent fundraising, which could lead to further dilution and stock price declines.

BioAtla, Inc. (BCAB)

Score: 95/100 (CRITICAL). Cash runway: 0.3 months. Shares up 73.8% over 3 years. 4 dilution filings in 12 months. BCAB has a 0.3-month cash runway and 4 filings in 12 months, indicating frequent capital raising. The company’s 73.8% share price increase over three years suggests investor optimism, but the low cash runway and multiple filings highlight the risk of dilution.

Watch the cash, not the price.

BCAB’s 0.3-month cash runway is extremely low, and the 4 filings in 12 months suggest ongoing capital needs. The company has seen a 73.8% share price increase, but this could be unsustainable if further dilution occurs. The risk is high, and investors should monitor the company’s capital raising strategy closely.

The Deepest Dive

SLXN’s 73,953.9% warrant coverage is the most concerning figure. That level of coverage means a massive potential increase in shares outstanding if warrants are exercised. With a 2.5-month cash runway and 10 dilution filings in 12 months, the company is in a precarious position. The market may not react well to further dilution, and the share price could drop sharply if the company fails to raise capital or if the warrants are exercised.

That math is brutal.

The combination of extreme warrant coverage, a short cash runway, and frequent dilution filings makes SLXN the most risky stock in the group. If the company cannot secure additional capital, the share price could be severely impacted. Investors should be wary of the company’s financial position and the potential for further dilution.

What Moved Scores This Week

SLXN’s score increased to 98/100 due to the 73,953.9% warrant coverage and 10 dilution filings. ERNA’s score remained at 99/100, but its 523% warrant coverage remains a critical risk. ECDA’s score stayed at 100/100, with its 0.2-month cash runway and 43.7% warrant coverage still in place. The scores reflect the ongoing dilution risks in the group, with some companies showing worsening conditions.

Watch the cash, not the price.

Several companies saw their scores remain unchanged, but the underlying data remains alarming. The high levels of warrant coverage and low cash runways suggest that the dilution risk is not improving. The market may react negatively to further dilution, and investors should be cautious about the long-term viability of these companies.

Investor Framework

Investors should look for improved cash runways, reduced warrant coverage, and fewer dilution filings before considering these stocks. A cash runway of at least 6 months would be a positive signal. Lower warrant coverage, ideally under 100%, would indicate a lower risk of dilution. Fewer than 3 dilution filings in 12 months would suggest more stable capital raising practices.

That math is brutal.

A company with a 6-month cash runway, 100% warrant coverage, and 3 or fewer dilution filings would be a more attractive investment. If these conditions improve, the dilution risk would be significantly reduced. Investors should monitor these metrics closely and avoid taking positions in companies that fail to meet these thresholds.

What Could Go Wrong

If the company raises $20M at market price before the ATM is triggered, the share price could drop sharply. The 73,953.9% warrant coverage means a large number of shares could be issued, leading to significant dilution. If the company fails to secure additional capital, the share price could collapse, and investors could suffer major losses.

That math is brutal.

If the market perceives the dilution as excessive, the stock could face a sell-off. The high levels of warrant coverage and low cash runways make these companies vulnerable to market sentiment. A negative reaction could lead to further price declines and increased risk for long positions.

What to Watch

Watch for an S-3 drawdown within 90 days if the stock price holds above $0.50. The company’s cash runway is extremely short, and the market may react negatively to further dilution. If the stock price remains stable, the company may need to raise capital quickly, which could lead to a significant share price drop.

That math is brutal.

Investors should monitor the company’s capital raising strategy and the market’s reaction to any new filings. A sudden drawdown or a large increase in shares could have a major impact on the stock price. The next 90 days will be critical for determining the company’s financial stability and investor confidence.

Redley's Take

My read: these companies are all in high-risk categories. The most important trigger to watch is whether SLXN raises $20M before its ATM is exhausted. If it does, the share price could drop significantly. This is a high-risk group, and investors should proceed with caution.

Track dilution risk before it hits your portfolio

DilutionWatch monitors shelf registrations, ATM offerings, warrant exercises, and cash runway across thousands of public companies — updated daily from SEC filings.

Get Full Access — Free Trial →
← Back to Intel
Not Financial Advice: This article is for informational and educational purposes only and does not constitute financial advice, investment advice, or a recommendation to buy or sell any security. DilutionWatch provides SEC filing data and dilution analysis tools for research purposes only — all investment decisions are made solely at your own risk. Guerilla Finance LLC is not a registered investment advisor or broker-dealer. Always consult a qualified financial professional before making investment decisions. Past performance is not indicative of future results.